Seek and Destroy: Relating Cancer Drivers to Therapies
A partir de données portant sur 6 792 échantillons tumoraux prélevés sur des patients atteints de cancer dans le cadre des projets "The Cancer Genome Atlas" et "International Cancer Genome Consortium", cette étude évalue les performances d'une approche numérique visant à guider la prescription d'une thérapie ciblée en fonction de l'identification d'anomalies génomiques pertinentes dans une tumeur
In this issue of Cancer Cell, Rubio-Perez and colleagues present an in silico prescription strategy based on identifying somatic driver alterations and druggability options. Although relatively few patients were found treatable following current clinical guidelines, many more could benefit from drug repurposing, considering compounds at various stages of (pre-)clinical investigation.
Cancer Cell , commentaire, 2014